Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

6-Hydroxydopamine (6-OHDA) is widely used to selectively lesion dopaminergic neurons of the substantia nigra (SN) in the creation of animal models of Parkinson’s disease. In vitro , the death of PC-12 cells caused by exposure to 6-OHDA occurs with characteristics consistent with an apoptotic mechanism of cell death. To test the hypothesis that apoptotic pathways are involved in the death of dopaminergic neurons of the SN caused by 6-OHDA, we created a replication-defective genomic herpes simplex virus-based vector containing the coding sequence for the antiapoptotic peptide Bcl-2 under the transcriptional control of the simian cytomegalovirus immediate early promoter. Transfection of primary cortical neurons in culture with the Bcl-2-producing vector protected those cells from naturally occurring cell death over 3 weeks. Injection of the Bcl-2-expressing vector into SN of rats 1 week before injection of 6-OHDA into the ipsilateral striatum increased the survival of neurons in the SN, detected either by retrograde labeling of those cells with fluorogold or by tyrosine hydroxylase immunocytochemistry, by 50%. These results, demonstrating that death of nigral neurons induced by 6-OHDA lesioning may be blocked by the expression of Bcl-2, are consistent with the notion that cell death in this model system is at least in part apoptotic in nature and suggest that a Bcl-2-expressing vector may have therapeutic potential in the treatment of Parkinson’s disease.

Bibliography

Yamada, M., Oligino, T., Mata, M., Goss, J. R., Glorioso, J. C., & Fink, D. J. (1999). Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proceedings of the National Academy of Sciences, 96(7), 4078–4083.

Authors 6
  1. Masanobu Yamada (first)
  2. Thomas Oligino (additional)
  3. Marina Mata (additional)
  4. James R. Goss (additional)
  5. Joseph C. Glorioso (additional)
  6. David J. Fink (additional)
References 43 Referenced 93
  1. 10.1126/science.6610213
  2. 10.1016/0024-3205(85)90146-8
  3. 10.1016/0014-2999(68)90164-7
  4. 10.1016/0006-8993(70)90187-3
  5. 10.1006/neur.1995.0016
  6. 10.1016/0306-4522(94)90605-X
  7. 10.1016/0361-9230(91)90242-C
  8. 10.1016/0361-9230(91)90164-F
  9. 10.1006/exnr.1998.6848
  10. 10.1523/JNEUROSCI.17-06-02030.1997
  11. 10.1016/0306-4522(94)90566-5
  12. 10.1016/S0006-8993(96)01358-3
  13. 10.1046/j.1471-4159.1998.70062637.x
  14. 10.1172/JCI117946
  15. 10.1002/mds.870120105
  16. 10.1126/science.281.5381.1322
  17. 10.1038/42867
  18. 10.1038/nm0697-614
  19. 10.1023/A:1026390201168
  20. 10.1002/(SICI)1098-2396(199702)25:2<176::AID-SYN8>3.0.CO;2-9
  21. 10.1073/pnas.95.10.5789
  22. 10.1128/jvi.67.1.516-529.1993
  23. 10.1128/jvi.56.2.558-570.1985
  24. D Krisky, P Marconi, W F Goins, J C Glorioso Methods in Molecular Medicine, Gene Therapy Protocols (Humana, Totowa, NJ), pp. 79–102 (1996). / Methods in Molecular Medicine, Gene Therapy Protocols by Krisky D (1996)
  25. 10.1073/pnas.93.21.11319
  26. 10.1523/JNEUROSCI.18-20-08145.1998
  27. 10.1073/pnas.92.19.8935
  28. 10.1126/science.275.5301.838
  29. 10.1073/pnas.94.16.8818
  30. 10.1073/pnas.94.25.14083
  31. 10.1074/jbc.272.8.4680
  32. 10.1002/jnr.490400216
  33. 10.1016/0092-8674(93)80066-N
  34. 10.1002/ana.410380604
  35. 10.1046/j.1471-4159.1996.67031259.x
  36. 10.1073/pnas.93.18.9893
  37. 10.1038/nm0397-357
  38. 10.1146/annurev.ne.19.030196.001405
  39. J C Glorioso, D J Fink Advances in Pharmacology: Gene Therapy, eds J T August, M W Anders, F Munrad, J T Coyle (Academic, San Diego, 1996). / Advances in Pharmacology: Gene Therapy by Glorioso J C (1996)
  40. 10.1016/0022-510X(95)00336-Z
  41. P Anglade, S Vyas, F Javoy-Agid, M T Herrero, P P Michel, J Marquez, A Mouatt-Prigent, M Ruberg, E C Hirsch, Y Agid Histol Histopathol 12, 25–31 (1997). / Histol Histopathol by Anglade P (1997)
  42. P Anglade, S Vyas, E C Hirsch, Y Agid Histol Histopathol 12, 603–610 (1997). / Histol Histopathol by Anglade P (1997)
  43. M M Tompkins, E J Basgall, E Zamrini, W D Hill Am J Pathol 150, 119–131 (1997). / Am J Pathol by Tompkins M M (1997)
Dates
Type When
Created 23 years ago (July 26, 2002, 10:42 a.m.)
Deposited 3 years, 4 months ago (April 13, 2022, 5:45 p.m.)
Indexed 1 year ago (Aug. 7, 2024, 1:51 p.m.)
Issued 26 years, 4 months ago (March 30, 1999)
Published 26 years, 4 months ago (March 30, 1999)
Published Online 26 years, 4 months ago (March 30, 1999)
Published Print 26 years, 4 months ago (March 30, 1999)
Funders 0

None

@article{Yamada_1999, title={Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo}, volume={96}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.96.7.4078}, DOI={10.1073/pnas.96.7.4078}, number={7}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Yamada, Masanobu and Oligino, Thomas and Mata, Marina and Goss, James R. and Glorioso, Joseph C. and Fink, David J.}, year={1999}, month=mar, pages={4078–4083} }